NYSE:RCUSBiotechs
A Look At Arcus Biosciences (RCUS) Valuation After Morgan Stanley Downgrade And Phase 3 Trial Discontinuation
Morgan Stanley’s downgrade of Arcus Biosciences (RCUS) following the discontinuation of a key Phase 3 trial has put the stock under closer scrutiny, just as the company outlines fresh 2026 pipeline priorities and data milestones.
See our latest analysis for Arcus Biosciences.
The latest pullback, with a 7 day share price return of negative 9.8% and 30 day share price return of negative 16.4%, follows the Phase 3 setback and Morgan Stanley downgrade. At the same time, the 90 day share price...